Little Green Pharma (LGP) has confirmed it will remain one of just two approved suppliers to the French medicinal cannabis market for at least twelve more months, after Paris formally submitted a regulatory framework for a medical cannabis market to the European Commission (EC).
LGP described the document sent to the EC as a "critical step" toward creating a "pathway for regulatory approval and structured market access".
Under the proposed framework, all medicinal cannabis products sold in France will need a Common Technical Document (CTD) before they can be prescribed to patients.
LGP noted that the "significant information and data requirements" of the CTD process are expected to limit the number of companies that can enter the market.
A transition period has been extended to March 31, 2026, "during which time LGP will continue to be one of only two company's supplying products at full price".
The Western Australia-based company has consistently promoted its participation in France's medicinal cannabis trial, reassuring investors that its early entry into the market has positioned it well for sustained success over the long term.
LGP has been delivering product into France since 2021.
"Leveraging its extensive experience and strong partnerships with French distributors, healthcare providers and regulatory authorities, LGP is well-positioned to capitalise on the evolving market landscape," it said.
"This development underscores LGP's long-term strategic vision for France and reaffirms its commitment to supplying high-quality medicinal cannabis products to patients in need."
